Key Events This Week
1 June: Q4 FY26 results reveal exceptional income masking operational weakness
1 June: MarketsMOJO upgrades rating to Sell on improved technicals and valuation
5 June: Stock rallies 3.11% on strong volume, closing at Rs.35.52
Aug 07, 03:30 PM
BSE+NSE Vol: 6.76 k

Biofil Chemicals & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 30 July 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 04 August 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news article
Biofil Chemicals & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Biofil Chemicals & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 July 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Biofil Chemicals & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Read full news article
Biofil Chemicals & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Read full news article
1 June: Q4 FY26 results reveal exceptional income masking operational weakness
1 June: MarketsMOJO upgrades rating to Sell on improved technicals and valuation
5 June: Stock rallies 3.11% on strong volume, closing at Rs.35.52
Biofil Chemicals & Pharmaceuticals Ltd's latest financial results for Q4 FY26 reveal a complex picture of operational performance. The company reported net sales of ₹7.57 crores, reflecting a significant quarter-on-quarter growth of 780.23% from the previous quarter's ₹0.86 crores. However, this surge is contrasted by a year-on-year decline of 9.34%, indicating ongoing demand challenges despite the apparent recovery. Net profit for the quarter stood at ₹0.21 crores, which is a 162.50% increase compared to the previous quarter, and a 5.00% increase year-on-year. While this uptick in profit may seem positive, it is essential to note that the overall operational performance remains inconsistent. The operating margin decreased to 5.68% from 11.63% in the prior quarter, suggesting rising input costs or unfavorable product mix despite higher sales. The volatility in revenue is a critical concern, with sales flu...
Read full news article
Biofil Chemicals & Pharmaceuticals Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹57.00 crores, reported net profit of ₹0.21 crores in Q4 FY26 (Mar'26), marking a modest 5.00% increase year-on-year but a substantial 162.50% surge quarter-on-quarter. However, this apparent profitability improvement conceals deeper operational challenges, as the company's core business performance remains under significant pressure with volatile revenue patterns and contracting margins.
Read full news article
Biofil Chemicals & Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a nuanced shift in its technical outlook and valuation metrics despite ongoing fundamental challenges. The upgrade, effective from 29 May 2026, is driven primarily by improved technical indicators and a more attractive valuation grade, while financial trends and quality scores remain subdued.
Read full news articleBiofil Chemicals & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 inter alia to consider and approve the Un-Audited Financial Results of the Company for the first Quarter ended on 30th June 2026 along with Limited Review Report thereon. 2. To consider other routine matters with the permission of the chair.
Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depository and Participants) Regulations 2018 for the quarter ended 30th June 2026.
Closure of Trading Window for the quarter ended 30.06.2026
11 Aug 2026
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available